Developer docs
API playgroundTry for free, no card

Search company profiles

Haima Therapeutics

Full company profile

uuid0002cqy

Namestring
Haima Therapeutics
Legal namestring
Haima Therapeutics, LLC
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Haima Therapeutics, LLC is a preclinical-stage biopharmaceutical company founded in 2016 in Cleveland, Ohio, developing cell-inspired therapies for the treatment of bleeding and blood-related diseases. The company's lead product, SynthoPlate, is a fully synthetic, IV-injectable hemostatic nanoparticle that mimics and amplifies platelet adhesion (via CBP and VBP peptides) and aggregation (via GPIIb-IIIa-mimicking FMP peptide) functions. The technology uses proprietary peptide-decorated liposomes that can be stored as liquid or lyophilized powder, with 12+ months shelf stability and reconstitution in under one minute. The platform is exclusively licensed from Case Western Reserve University, where co-founder and CTO Anirban Sen Gupta invented the technology in the Department of Biomedical Engineering.

Haima's target indications span multiple high-burden clinical scenarios: pre-hospital trauma hemorrhage, complex surgical bleeding, thrombocytopenia (over 750,000 US patients annually receive donor platelet transfusions), traumatic brain injury in patients on antiplatelet therapy, von Willebrand disease, and military battlefield hemorrhage control. The company also operates a broader Platelet-Inspired Platform Technology extending into thrombosis, thromboinflammation, and cancer metastasis applications. Distribution upon regulatory approval will target trauma centers, hospitals, and healthcare systems via enterprise field sales, alongside military medical supply chains and veterinary clinics.

The company has been funded entirely through approximately $61M+ in non-dilutive SBIR grants and government contracts from NIH, NSF, DoD, and DARPA, including integration into the $46M DARPA FSHARP whole blood surrogate program. Haima is currently raising a Series A round to advance SynthoPlate toward IND submission planned for early 2027, with first-in-human clinical trials to follow. The company employs 1-10 people and is led by CEO Michael Bruckman, PhD, alongside CMO Dr. Matthew Neal, COO Christa Pawlowski, PhD, CTO Anirban Sen Gupta, PhD, and Executive Chair Timothy Pelura, PhD.

Short descriptiontext

Haima Therapeutics is a preclinical-stage biopharmaceutical company developing SynthoPlate, a fully synthetic IV-injectable platelet surrogate for hemorrhage control in trauma, surgery, thrombocytopenia, and military battlefield applications, advancing toward IND submission in 2027.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCleveland, United States
HQ citystring
Cleveland
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
synthetic platelet technology, hemostatic drug development, trauma hemorrhage control, platelet surrogate therapeutics, biopharmaceutical research
Industry1 code
PRIMARYHLAAAAAL
Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Hemostatic Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue from commercial sale of SynthoPlate as an IV-injectable hemostatic drug for trauma, surgery, and thrombocytopenia indications. Company is preclinical stage; no commercial products yet.

haimatherapeutics.com
2Licensing Royalties
TypeLicensing Royalties
Description

Exclusive license agreement with Case Western Reserve University for synthetic platelet technology. May generate licensing revenue from the technology platform.

haimatherapeutics.com
3Government Contracts and SBIR Grants
TypeProfessional Services
Description

Non-dilutive funding from DARPA, DoD, NIH, and NSF SBIR awards supporting development. Multiple grants totaling over $10M to advance SynthoPlate toward clinical use.

haimatherapeutics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1SynthoPlate
Description

A platelet-inspired, IV-injectable fully-synthetic hemostatic agent that mimics and amplifies platelet adhesion and aggregation functions to stop bleeding in patients with low platelet counts or platelet dysfunction.

haimatherapeutics.com
Core offering1 text field

Haima Therapeutics is developing SynthoPlate, a fully-synthetic, IV-injectable hemostatic agent that mimics and amplifies platelet adhesion and aggregation functions to stop bleeding in patients with traumatic injury, surgery, thrombocytopenia, and rare bleeding disorders. The technology uses peptide-decorated liposomes (CBP, VBP, FMP) and can be stored as liquid or lyophilized powder for shelf-stable, field-deployable use.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Reduced blood loss by ~56% in rat liver laceration model with lyophilized SynthoPlate via intraosseous injection
+4 more records
Product overview1 text field

Haima Therapeutics is a pre-clinical stage biopharma company developing cell-inspired therapies for bleeding treatment and blood-related diseases. The company operates with two main offerings: (1) SynthoPlate, a fully-synthetic, nanoparticle-based hemostatic agent that serves as a platelet surrogate to mitigate bleeding by acting at injury sites and amplifying natural clotting mechanisms; and (2) a Platelet-Inspired Platform Technology that enables targeted drug delivery across multiple therapeutic applications. SynthoPlate is the company's lead product targeting traumatic injury, surgery, and thrombocytopenia indications. The technology was licensed from Case Western Reserve University and is advancing toward IND submission in early 2027 with support from DARPA and NIH funding.

Product and service1 record
1SynthoPlate
CategoryHemostatic drug product (lead candidate)
Description

SynthoPlate is a fully-synthetic, IV-injectable hemostatic agent that mimics and amplifies platelet adhesion and aggregation functions to stop bleeding in patients with low platelet counts or platelet dysfunction. It targets traumatic injury, surgery, and thrombocytopenia indications and can be stored as liquid or lyophilized powder for shelf-stable, field-deployable use.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-02-01
Description

Haima is an integral part of DARPA's $46M FSHARP (Fieldable Solutions for Hemorrhage with bio-Artificial Resuscitation Products) program led by University of Maryland, Baltimore. Haima's role focuses on the hemorrhage control component by providing SynthoPlate as part of a whole blood surrogate alongside oxygen-carrying and plasma components.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-02-01
Description

Lead institution for DARPA FSHARP program. Collaborating with Haima to develop a shelf-stable whole blood equivalent combining SynthoPlate with oxygen-carrying and plasma components.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-02-01
Description

Collaboration on ErythroMer (red blood cell surrogate) co-administration with SynthoPlate. Evaluating fully dried whole blood surrogate (WBS) combining Haima's synthetic platelets with ErythroMer and lyophilized plasma for field-deployable resuscitation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-02-01
Description

Multi-year collaboration with Dr. Matthew Neal (Co-investigator) at Pittsburgh Trauma Research Center. Dr. Neal serves as CMO of Haima and collaborates on preclinical and clinical development of SynthoPlate. Also consortium partner in DARPA FSHARP program.

Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2023-02-01
Description

FSHARP consortium partner providing preclinical development services and expertise.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-02-01
Description

FSHARP consortium partner contributing to whole blood surrogate development.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-02-01
Description

FSHARP consortium partner in whole blood surrogate development.

8Ohio State University
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-02-01
Description

FSHARP consortium partner contributing research expertise.

haimatherapeutics.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-02-01
Description

FSHARP consortium partner providing research capabilities.

10University of California San Diego
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-02-01
Description

FSHARP consortium partner contributing academic research expertise.

haimatherapeutics.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-09-30
Description

DoD MRDC awarded $1.4M cooperative agreement to evaluate co-administration of SynthoPlate with lyophilized plasma to create HELP (Hemostatically Enhanced Lyophilized Plasma) product in collaboration with Dr. Michael A. Meledeo at USAISR, San Antonio.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-09-30
Description

DoD CRRP $1.6M research contract to evaluate co-administration of SynthoPlate with ErythroMer and lyophilized plasma for fully dried whole blood surrogate (WBS) in collaboration with Drs. Allan Doctor and Dipanjan Pan.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-09-30
Description

KaloCyte developed ErythroMer, a novel red blood cell surrogate. Haima collaborating to evaluate co-administration of SynthoPlate with ErythroMer and lyophilized plasma for fully dried whole blood surrogate.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2020-04-27
Description

Exclusive license agreement for SynthoPlate synthetic platelet technology developed by Professor Anirban Sen Gupta in CWRU's Department of Biomedical Engineering. Haima licensed the technology for research, development, and commercialization of hemostatic therapies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Commercializing Veti-Gel, a plant-based hemostatic gel for rapid bleeding control in trauma and surgical settings. Comparable as a synthetic/biomimetic hemostasis company targeting both human and veterinary hemorrhage with novel, non-donor-dependent mechanisms.

TypeDirect peer
Description

Developer of ErythroMer, a freeze-dried red blood cell surrogate. Direct FSHARP consortium partner with Haima, co-developing a field-deployable whole blood surrogate. Highly comparable as a synthetic blood component company targeting trauma and military applications.

TypeBroad incumbent
Description

Global leader in blood plasma-derived and recombinant biologic therapies for hemophilia, von Willebrand disease, and thrombocytopenia. Comparable as a broad incumbent operating across Haima's primary indications and a likely strategic acquirer or commercialization partner for SynthoPlate.

TypeDirect peer
Description

Developing spray-dried plasma technologies for transfusion medicine. Direct partner-adjacent peer in the dried/shelf-stable blood surrogate space and a fellow FSHARP-aligned collaborator targeting pre-hospital and battlefield resuscitation.

TypeBroad incumbent
Description

Major plasma products and blood-component manufacturer with a broad hemostasis franchise. Comparable as a large incumbent whose plasma-derived and recombinant hemostatic products address overlapping indications and which could potentially distribute or partner SynthoPlate post-approval.

TypeDirect peer
Description

Developing Thrombosomes, a lyophilized platelet product for hemostasis in surgery and trauma. Most directly comparable to Haima's SynthoPlate as a synthetic/lyophilized platelet surrogate targeting hemorrhage control, with overlapping clinical indications and similar biopreservation/formulation challenges.

TypeDirect peer
Description

Developing AC5, a self-assembling peptide hemostatic agent. Comparable as an early-stage synthetic hemostatic technology targeting surgical and trauma bleeding with a novel non-blood-derived mechanism of action.

TypeBroad incumbent
Description

Privately-held global manufacturer of human proteins and coagulation factor products, including therapies for von Willebrand disease. Comparable as a broad blood-product incumbent overlapping SynthoPlate's hematology indications and a candidate strategic partner.

TypeEmerging player
Description

Developing synthetic coagulant factor therapies for bleeding disorders. Comparable as an emerging biotech pursuing synthetic alternatives to blood-derived coagulation products, though focused on factor replacement rather than platelet mimicry.

TypeBroad incumbent
Description

Global pharmaceutical company with a large hematology franchise covering hemophilia, thrombocytopenia, and rare bleeding disorders. Comparable as a broad incumbent operating across many of Haima's target indications and a likely M&A or licensing partner for an approved synthetic platelet product.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Haima Therapeutics

Hemostatic Biopharmaceuticalshaimatherapeutics.com

Haima Therapeutics is a preclinical-stage biopharmaceutical company developing SynthoPlate, a fully synthetic IV-injectable platelet surrogate for hemorrhage control in trauma, surgery, thrombocytopenia, and military battlefield applications, advancing toward IND submission in 2027.

What Haima Therapeutics does

Haima Therapeutics, LLC is a preclinical-stage biopharmaceutical company founded in 2016 in Cleveland, Ohio, developing cell-inspired therapies for the treatment of bleeding and blood-related diseases. The company's lead product, SynthoPlate, is a fully synthetic, IV-injectable hemostatic nanoparticle that mimics and amplifies platelet adhesion (via CBP and VBP peptides) and aggregation (via GPIIb-IIIa-mimicking FMP peptide) functions. The technology uses proprietary peptide-decorated liposomes that can be stored as liquid or lyophilized powder, with 12+ months shelf stability and reconstitution in under one minute. The platform is exclusively licensed from Case Western Reserve University, where co-founder and CTO Anirban Sen Gupta invented the technology in the Department of Biomedical Engineering.

Haima's target indications span multiple high-burden clinical scenarios: pre-hospital trauma hemorrhage, complex surgical bleeding, thrombocytopenia (over 750,000 US patients annually receive donor platelet transfusions), traumatic brain injury in patients on antiplatelet therapy, von Willebrand disease, and military battlefield hemorrhage control. The company also operates a broader Platelet-Inspired Platform Technology extending into thrombosis, thromboinflammation, and cancer metastasis applications. Distribution upon regulatory approval will target trauma centers, hospitals, and healthcare systems via enterprise field sales, alongside military medical supply chains and veterinary clinics.

The company has been funded entirely through approximately $61M+ in non-dilutive SBIR grants and government contracts from NIH, NSF, DoD, and DARPA, including integration into the $46M DARPA FSHARP whole blood surrogate program. Haima is currently raising a Series A round to advance SynthoPlate toward IND submission planned for early 2027, with first-in-human clinical trials to follow. The company employs 1-10 people and is led by CEO Michael Bruckman, PhD, alongside CMO Dr. Matthew Neal, COO Christa Pawlowski, PhD, CTO Anirban Sen Gupta, PhD, and Executive Chair Timothy Pelura, PhD.

Haima Therapeutics firmographics

Firmographics
Name
Haima Therapeutics
Legal name
Haima Therapeutics, LLC
Website
https://haimatherapeutics.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Haima Therapeutics is a preclinical-stage biopharmaceutical company developing SynthoPlate, a fully synthetic IV-injectable platelet surrogate for hemorrhage control in trauma, surgery, thrombocytopenia, and military battlefield applications, advancing toward IND submission in 2027.
Ownership category
akta.pro rank

Haima Therapeutics industry classification

Industry
Product category
Hemostatic Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAL
Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Synthetic platelet technology
  • Hemostatic drug development
  • Trauma hemorrhage control
  • Platelet surrogate therapeutics
  • Biopharmaceutical research

Where Haima Therapeutics is headquartered

Location

Headquarters

HQ city
Cleveland
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Haima Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Revenue from commercial sale of SynthoPlate as an IV-injectable hemostatic drug for trauma, surgery, and thrombocytopenia indications. Company is preclinical stage; no commercial products yet.
  2. Licensing Royalties: Exclusive license agreement with Case Western Reserve University for synthetic platelet technology. May generate licensing revenue from the technology platform.
  3. Government Contracts and SBIR Grants: Non-dilutive funding from DARPA, DoD, NIH, and NSF SBIR awards supporting development. Multiple grants totaling over $10M to advance SynthoPlate toward clinical use.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Haima Therapeutics product offering

Product offering

Core offering

Haima Therapeutics is developing SynthoPlate, a fully-synthetic, IV-injectable hemostatic agent that mimics and amplifies platelet adhesion and aggregation functions to stop bleeding in patients with traumatic injury, surgery, thrombocytopenia, and rare bleeding disorders. The technology uses peptide-decorated liposomes (CBP, VBP, FMP) and can be stored as liquid or lyophilized powder for shelf-stable, field-deployable use.

Product overview

Haima Therapeutics is a pre-clinical stage biopharma company developing cell-inspired therapies for bleeding treatment and blood-related diseases. The company operates with two main offerings: (1) SynthoPlate, a fully-synthetic, nanoparticle-based hemostatic agent that serves as a platelet surrogate to mitigate bleeding by acting at injury sites and amplifying natural clotting mechanisms; and (2) a Platelet-Inspired Platform Technology that enables targeted drug delivery across multiple therapeutic applications. SynthoPlate is the company's lead product targeting traumatic injury, surgery, and thrombocytopenia indications. The technology was licensed from Case Western Reserve University and is advancing toward IND submission in early 2027 with support from DARPA and NIH funding.

Differentiator

Problem solved

Functional benefit

Brands

  • SynthoPlate: A platelet-inspired, IV-injectable fully-synthetic hemostatic agent that mimics and amplifies platelet adhesion and aggregation functions to stop bleeding in patients with low platelet counts or platelet dysfunction.

Products and services

  • SynthoPlate SynthoPlate is a fully-synthetic, IV-injectable hemostatic agent that mimics and amplifies platelet adhesion and aggregation functions to stop bleeding in patients with low platelet counts or platelet dysfunction. It targets traumatic injury, surgery, and thrombocytopenia indications and can be stored as liquid or lyophilized powder for shelf-stable, field-deployable use.

Quantifiable outcome

  • Reduced blood loss by ~56% in rat liver laceration model with lyophilized SynthoPlate via intraosseous injection
  • +4 more outcomes

Companies that use Haima Therapeutics

Customer profile

Segments6 records

Ideal customer profiles3 records

Haima Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Haima Therapeutics partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered flagship, core and minor.

  • DARPA (FSHARP Program)flagshipStrategic or Co-development Partner · 1 February 2023Haima is an integral part of DARPA's $46M FSHARP (Fieldable Solutions for Hemorrhage with bio-Artificial Resuscitation Products) program led by University of Maryland, Baltimore. Haima's role focuses on the hemorrhage control component by providing SynthoPlate as part of a whole blood surrogate alongside oxygen-carrying and plasma components.
  • University of Maryland, BaltimorecoreStrategic or Co-development Partner · 1 February 2023Lead institution for DARPA FSHARP program. Collaborating with Haima to develop a shelf-stable whole blood equivalent combining SynthoPlate with oxygen-carrying and plasma components.
  • KaloCyte Inc.coreStrategic or Co-development Partner · 1 February 2023Collaboration on ErythroMer (red blood cell surrogate) co-administration with SynthoPlate. Evaluating fully dried whole blood surrogate (WBS) combining Haima's synthetic platelets with ErythroMer and lyophilized plasma for field-deployable resuscitation.
  • University of PittsburghcoreStrategic or Co-development Partner · 1 February 2023Multi-year collaboration with Dr. Matthew Neal (Co-investigator) at Pittsburgh Trauma Research Center. Dr. Neal serves as CMO of Haima and collaborates on preclinical and clinical development of SynthoPlate. Also consortium partner in DARPA FSHARP program.
  • Charles River LaboratoriesminorImplementation/ SI/ Consulting Partner · 1 February 2023FSHARP consortium partner providing preclinical development services and expertise.
  • Teleflex IncorporatedminorStrategic or Co-development Partner · 1 February 2023FSHARP consortium partner contributing to whole blood surrogate development.
  • Latham Biopharm GroupminorStrategic or Co-development Partner · 1 February 2023FSHARP consortium partner in whole blood surrogate development.
  • Ohio State UniversityminorStrategic or Co-development Partner · 1 February 2023FSHARP consortium partner contributing research expertise.
  • Southwest Research InstituteminorStrategic or Co-development Partner · 1 February 2023FSHARP consortium partner providing research capabilities.
  • University of California San DiegominorStrategic or Co-development Partner · 1 February 2023FSHARP consortium partner contributing academic research expertise.
  • U.S. Army Institute of Surgical Research (USAISR)coreStrategic or Co-development Partner · 30 September 2020DoD MRDC awarded $1.4M cooperative agreement to evaluate co-administration of SynthoPlate with lyophilized plasma to create HELP (Hemostatically Enhanced Lyophilized Plasma) product in collaboration with Dr. Michael A. Meledeo at USAISR, San Antonio.
  • University of Maryland - Baltimore (Doctors Allan Doctor and Dipanjan Pan)coreStrategic or Co-development Partner · 30 September 2020DoD CRRP $1.6M research contract to evaluate co-administration of SynthoPlate with ErythroMer and lyophilized plasma for fully dried whole blood surrogate (WBS) in collaboration with Drs. Allan Doctor and Dipanjan Pan.
  • KaloCyte Inc. (ErythroMer Developer)coreStrategic or Co-development Partner · 30 September 2020KaloCyte developed ErythroMer, a novel red blood cell surrogate. Haima collaborating to evaluate co-administration of SynthoPlate with ErythroMer and lyophilized plasma for fully dried whole blood surrogate.
  • Case Western Reserve UniversitycoreOEM/ Whitelabel/ Licensing Partner · 27 April 2020Exclusive license agreement for SynthoPlate synthetic platelet technology developed by Professor Anirban Sen Gupta in CWRU's Department of Biomedical Engineering. Haima licensed the technology for research, development, and commercialization of hemostatic therapies.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Haima Therapeutics competitors and assessment

Company assessment

Direct peers

  • Cresilon (formerly Cresilon Inc.): Commercializing Veti-Gel, a plant-based hemostatic gel for rapid bleeding control in trauma and surgical settings. Comparable as a synthetic/biomimetic hemostasis company targeting both human and veterinary hemorrhage with novel, non-donor-dependent mechanisms.
  • KaloCyte Inc. Developer of ErythroMer, a freeze-dried red blood cell surrogate. Direct FSHARP consortium partner with Haima, co-developing a field-deployable whole blood surrogate. Highly comparable as a synthetic blood component company targeting trauma and military applications.
  • Velico Medical: Developing spray-dried plasma technologies for transfusion medicine. Direct partner-adjacent peer in the dried/shelf-stable blood surrogate space and a fellow FSHARP-aligned collaborator targeting pre-hospital and battlefield resuscitation.
  • Cellphire Therapeutics: Developing Thrombosomes, a lyophilized platelet product for hemostasis in surgery and trauma. Most directly comparable to Haima's SynthoPlate as a synthetic/lyophilized platelet surrogate targeting hemorrhage control, with overlapping clinical indications and similar biopreservation/formulation challenges.
  • Arch Therapeutics: Developing AC5, a self-assembling peptide hemostatic agent. Comparable as an early-stage synthetic hemostatic technology targeting surgical and trauma bleeding with a novel non-blood-derived mechanism of action.

Broad incumbents

  • CSL Behring: Global leader in blood plasma-derived and recombinant biologic therapies for hemophilia, von Willebrand disease, and thrombocytopenia. Comparable as a broad incumbent operating across Haima's primary indications and a likely strategic acquirer or commercialization partner for SynthoPlate.
  • Grifols: Major plasma products and blood-component manufacturer with a broad hemostasis franchise. Comparable as a large incumbent whose plasma-derived and recombinant hemostatic products address overlapping indications and which could potentially distribute or partner SynthoPlate post-approval.
  • Octapharma: Privately-held global manufacturer of human proteins and coagulation factor products, including therapies for von Willebrand disease. Comparable as a broad blood-product incumbent overlapping SynthoPlate's hematology indications and a candidate strategic partner.
  • Takeda Pharmaceutical (Baxalta/Shire hematology franchise): Global pharmaceutical company with a large hematology franchise covering hemophilia, thrombocytopenia, and rare bleeding disorders. Comparable as a broad incumbent operating across many of Haima's target indications and a likely M&A or licensing partner for an approved synthetic platelet product.

Emerging players

  • Coagulant Therapeutics: Developing synthetic coagulant factor therapies for bleeding disorders. Comparable as an emerging biotech pursuing synthetic alternatives to blood-derived coagulation products, though focused on factor replacement rather than platelet mimicry.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Haima Therapeutics social profiles

Digital presence

Haima Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Haima Therapeutics leadership team

Management profile

Number of profiles

Profiles10 records

Haima Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Haima Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Haima Therapeutics

What does Haima Therapeutics do?

Haima Therapeutics is developing SynthoPlate, a fully-synthetic, IV-injectable hemostatic agent that mimics and amplifies platelet adhesion and aggregation functions to stop bleeding in patients with traumatic injury, surgery, thrombocytopenia, and rare bleeding disorders. The technology uses peptide-decorated liposomes (CBP, VBP, FMP) and can be stored as liquid or lyophilized powder for shelf-stable, field-deployable use.

Is Haima Therapeutics a public or private company?

Haima Therapeutics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Haima Therapeutics founded?

Haima Therapeutics was founded in 2016. It employs 11 to 50 people.

Where is Haima Therapeutics based?

Haima Therapeutics is headquartered in Cleveland, United States, in the North America region.

How does Haima Therapeutics make money?

Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing Royalties and government Contracts and SBIR Grants.

Who are Haima Therapeutics's main competitors?

Direct peers on record are Cresilon (formerly Cresilon Inc.), KaloCyte Inc., Velico Medical, Cellphire Therapeutics and Arch Therapeutics. Broad incumbents are CSL Behring, Grifols, Octapharma and Takeda Pharmaceutical (Baxalta/Shire hematology franchise). Coagulant Therapeutics is listed as an emerging player.

Does Haima Therapeutics have an API?

No public API is recorded for Haima Therapeutics.

What industry is Haima Therapeutics in?

Haima Therapeutics's product category is Hemostatic Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAL, Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The DailyFirst-ever freeze-dried artificial platelets are shelf-stable and portable—a major advance for field medicineResearchers at Case Western Reserve, the University of Pittsburgh, and Haima Therapeutics developed freeze-dried synthetic platelets that remain effective for at least a year at room temperature and two months at 50°C. The team also tested direct injection into bone marrow, enabling rapid treatment without IV lines. Haima plans to apply for FDA approval for human clinical trials in 2027.The DailyScientists use synthetic platelets as ‘Trojan horse’ drug-delivery systemCase Western Reserve University researchers, in collaboration with biotechnology start-up Haima Therapeutics, developed a platelet-inspired nanoparticle drug-delivery system that doubled the effectiveness of brain-computer interface electrodes by delivering anti-inflammatory drugs directly to implanted sites. The synthetic platelets act as a "Trojan horse" to overcome the inflammation response that causes BCI electrodes to fail over time. Haima Therapeutics plans to begin human clinical trials in 2027 and received DARPA funding to advance the technology toward clinical translation, with potential applications for stroke, heart attack, and autoimmune disorders.DrugdiscoverytrendsPlatelet-inspired nanoparticle delivers drugs directly where they are neededResearchers at Case Western Reserve University and Haima Therapeutics developed a "platelet-inspired nanoparticle" that delivers an anti-inflammatory drug to improve brain-computer interface (BCI) electrode performance. This innovation doubled the effectiveness of the electrodes, which typically lose functionality due to inflammation from implantation. Haima Therapeutics plans to initiate human clinical trials for the nanoparticles in 2027.NewswiseScientists Use Synthetic Platelets as ‘Trojan Horse’ Drug-Delivery SystemScientists at Case Western Reserve University and Haima Therapeutics developed synthetic platelet-inspired nanoparticles to deliver anti-inflammatory drugs directly to brain implants, improving the performance of electrodes used in brain-computer interfaces (BCI). The targeted delivery doubled electrode effectiveness and was more beneficial than systemic drug delivery. Haima Therapeutics plans to initiate human clinical trials of the technology in 2027.EurekAlert!Scientists use synthetic platelets as ‘Trojan horse’ drug-delivery systemResearchers from Case Western Reserve University and Haima Therapeutics successfully used platelet-inspired nanoparticles to deliver anti-inflammatory drugs directly to brain-computer interface implants, doubling electrode effectiveness. This targeted approach addresses the inflammation barrier that typically causes implanted electrodes to fail over time. Haima Therapeutics plans to begin human clinical trials for this technology in 2027.clevelandNew CWRU, Haima Therapeutics' blood-clotting platelet simulators could save lives (video)Case Western Reserve University and Haima Therapeutics developed SynthoPlate, artificial platelet nanoparticles that mimic natural clotting. Haima will license the product, with U.S. military funding, and is conducting large-animal tests. Human trials are planned, with market launch expected in about three years.